ATE334681T1 - Verwendung von pteridinderivaten für die behandlung von erhöhtem hirndruck - Google Patents

Verwendung von pteridinderivaten für die behandlung von erhöhtem hirndruck

Info

Publication number
ATE334681T1
ATE334681T1 AT03788945T AT03788945T ATE334681T1 AT E334681 T1 ATE334681 T1 AT E334681T1 AT 03788945 T AT03788945 T AT 03788945T AT 03788945 T AT03788945 T AT 03788945T AT E334681 T1 ATE334681 T1 AT E334681T1
Authority
AT
Austria
Prior art keywords
increased
treatment
increatic
pressure
pteridine derivatives
Prior art date
Application number
AT03788945T
Other languages
English (en)
Inventor
Robert Doblhofer
Frank Tegtmeier
Original Assignee
Vasopharm Biotech Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vasopharm Biotech Gmbh filed Critical Vasopharm Biotech Gmbh
Application granted granted Critical
Publication of ATE334681T1 publication Critical patent/ATE334681T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C07D475/08—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
AT03788945T 2003-03-25 2003-10-08 Verwendung von pteridinderivaten für die behandlung von erhöhtem hirndruck ATE334681T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2003/003096 WO2005037286A1 (en) 2003-03-25 2003-03-25 Use of pteridine derivatives for the treatment of increased intracranial pressure and secondary ischemia

Publications (1)

Publication Number Publication Date
ATE334681T1 true ATE334681T1 (de) 2006-08-15

Family

ID=33040875

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03788945T ATE334681T1 (de) 2003-03-25 2003-10-08 Verwendung von pteridinderivaten für die behandlung von erhöhtem hirndruck

Country Status (14)

Country Link
US (3) US8222238B2 (de)
EP (1) EP1605947B1 (de)
JP (1) JP4630669B2 (de)
KR (1) KR101103888B1 (de)
CN (1) CN1758913B (de)
AT (1) ATE334681T1 (de)
AU (1) AU2003293607B2 (de)
CA (1) CA2519919C (de)
DE (1) DE60307327T2 (de)
ES (1) ES2270151T3 (de)
MX (1) MXPA05009491A (de)
PL (1) PL213123B1 (de)
RU (1) RU2348410C2 (de)
WO (2) WO2005037286A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005037286A1 (en) 2003-03-25 2005-04-28 Vasopharm Biotech Gmbh Use of pteridine derivatives for the treatment of increased intracranial pressure and secondary ischemia
RU2470642C2 (ru) * 2008-01-03 2012-12-27 Байомарин Фармасьютикл Инк. Аналоги птерина для лечения состояния, чувствительного к вн4
ES2586945T3 (es) 2014-03-31 2016-10-19 Vasopharm Gmbh Composiciones farmacéuticas sólidas que comprenden derivados de biopterina y usos de dichas composiciones
US12171766B2 (en) 2021-12-03 2024-12-24 Verinos Operations Gmbh Methods of treating patients suffering from brain injury and methods of increasing the value of the extended Glasgow Outcome Scale of patients suffering from brain injury
WO2023099013A1 (en) 2021-12-03 2023-06-08 Verinos Operations Gmbh Methods of treating patients suffering from brain injury and methods of increasing the value of the extended glasgow outcome scale of patients suffering from brain injury
WO2023214091A1 (en) 2022-05-06 2023-11-09 Verinos Operations Gmbh Methods of treating patients suffering from a disease condition or disorder that is associated with an increased glutamate level

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9203323A (es) * 1991-07-11 1994-07-29 Hoechst Ag El empleo de derivados de xantina para el tratamiento de lesiones secundarias de las celulas nerviosas y trastornos funcionales despues de traumas craneo-cerebrales.
US5266594A (en) * 1992-05-12 1993-11-30 Dawson Valina L Inhibitors of nitric oxide synthase and use thereof to prevent glutamate neurotoxicity
EP0674627A1 (de) * 1992-12-18 1995-10-04 The Wellcome Foundation Limited Pyrimidin-, pyridin-, pteridinon- und indazolderivate als enzyminhibitoren
US5527822A (en) 1993-12-29 1996-06-18 Forest Laboratories, Inc. Method of treatment of traumatic brain injury
DE4418097A1 (de) * 1994-05-24 1995-11-30 Cassella Ag Verwendung von Tetrahydropteridin-Derivaten als Hemmstoffe der NO-Synthase
DE4418096A1 (de) * 1994-05-24 1995-11-30 Cassella Ag Verwendung von Pteridin-Derivaten als Hemmstoffe der NO-Synthase
GB9500691D0 (en) 1995-01-13 1995-03-08 Smithkline Beecham Plc Compounds
GB9509156D0 (en) * 1995-05-05 1995-06-28 Sandoz Ltd Organic compounds
WO1997021711A1 (de) 1995-12-12 1997-06-19 Lonza Ag Verfahren zur herstellung von 4-aminopteridinderivaten
ZA9610741B (en) * 1995-12-22 1997-06-24 Warner Lambert Co 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists
DE69725721T3 (de) 1996-08-30 2007-10-31 Daiichi Asubio Pharma Co., Ltd. Vorbeugende oder heilende mittel für krankheiten, die durch mangel an stickoxid-synthase (nos) ausgelöst sind
WO1998028257A1 (en) 1996-12-24 1998-07-02 Chugai Seiyaku Kabushiki Kaisha Aromatic amine derivatives having nos inhibitory effect
AU735137B2 (en) * 1997-02-21 2001-07-05 Bayer Intellectual Property Gmbh Arylsulphonamides and analogues and their use for the treatment and neurovegetative disorders
DE19740785A1 (de) 1997-02-21 1998-08-27 Bayer Ag Arylsulfonamide und Analoga
US5922713A (en) * 1997-06-26 1999-07-13 Werner; Ernst Inhibition of nitric oxide synthase
ATE201412T1 (de) 1997-10-06 2001-06-15 Ernst Werner Pteridinderivate als no synthase-hemmer
DE19754573A1 (de) 1997-12-09 1999-06-10 Bayer Ag Pharmazeutische Zusammensetzung zur Behandlung von Schlaganfall und Schädel-Hirn-Trauma
DE19801646A1 (de) * 1998-01-17 1999-07-22 Bayer Ag Substituierte alpha,beta-annellierte Butyrolactone
HN1998000027A (es) * 1998-08-19 1999-06-02 Bayer Ip Gmbh Arilsulfonamidas y analagos
EP1144412B1 (de) * 1998-12-28 2004-09-29 4 AZA Bioscience nv Immunsuppressive wirkungen von pteridinderivaten
US6255280B1 (en) 1999-04-08 2001-07-03 University Of Kentucky Research Foundation Protection against traumatic brain injury
DE19944767A1 (de) * 1999-09-17 2001-03-29 Vasopharm Biotech Gmbh & Co Kg N-substituierte 4-Aminopteridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP1248556A2 (de) * 2000-01-07 2002-10-16 Rice Creek Medical, L.L.C. Nichtinvasives verfahren und gerät zur überwachung intrakranialen druckes
DE10109866A1 (de) 2001-03-01 2002-09-05 Abbott Gmbh & Co Kg Triazolverbindungen und deren Verwendung zur Prophylaxe und Therapie neurodegenerativer Erkrankungen, Hirntrauma und zerebraler Ischämie
DE60233949D1 (de) * 2001-08-20 2009-11-19 Biosite Inc Diagnostische marker für schlaganfall und hirntrauma sowie verfahren zur verwendung davon
WO2005037286A1 (en) 2003-03-25 2005-04-28 Vasopharm Biotech Gmbh Use of pteridine derivatives for the treatment of increased intracranial pressure and secondary ischemia

Also Published As

Publication number Publication date
AU2003293607B2 (en) 2009-12-03
US9422289B2 (en) 2016-08-23
DE60307327T2 (de) 2007-10-25
US20130131071A1 (en) 2013-05-23
JP4630669B2 (ja) 2011-02-09
WO2004084906A1 (en) 2004-10-07
CA2519919A1 (en) 2004-10-07
CN1758913B (zh) 2010-04-28
KR101103888B1 (ko) 2012-01-12
ES2270151T3 (es) 2007-04-01
US20070032498A1 (en) 2007-02-08
WO2005037286A1 (en) 2005-04-28
US8222238B2 (en) 2012-07-17
AU2003293607A1 (en) 2004-10-18
EP1605947B1 (de) 2006-08-02
CN1758913A (zh) 2006-04-12
EP1605947A1 (de) 2005-12-21
RU2005128956A (ru) 2006-04-27
MXPA05009491A (es) 2006-02-22
DE60307327D1 (de) 2006-09-14
US20130184281A1 (en) 2013-07-18
JP2006514965A (ja) 2006-05-18
PL378633A1 (pl) 2006-05-15
US9382252B2 (en) 2016-07-05
CA2519919C (en) 2009-09-08
RU2348410C2 (ru) 2009-03-10
PL213123B1 (pl) 2013-01-31
KR20060002861A (ko) 2006-01-09

Similar Documents

Publication Publication Date Title
ATE526991T1 (de) Zusammensetzungen und ihre verwendungen für die gentherapeutische behandlung von knochenerkrankungen
MXPA05010711A (es) Compuestos y composiciones novedosos como inhibidores de proteina-quinasa.
BRPI0518228A (pt) inibidores de cinesina mitótica e métodos de uso destes
BR0318383A (pt) derivados de pirazoloisoquinolina como inibidores de cinase
DE602005015862D1 (de) Verwendung von k-252a und kinasehemmern zur vorbeugung und behandlung von hmgb1-assoziierten pathologien
EA200700717A1 (ru) Сульфонамиды
TW200700422A (en) Compounds for inhibiting ksp kinesin activity
MX2007002470A (es) Fenilaminotiazoles sustituidos y su uso.
PA8599701A1 (es) Formas de dosificacion y procedimientos de tratamiento que usan inhibidores del vegfr
NO20055741D0 (no) Nye kjemiske forbindelser
ATE433966T1 (de) Methylendipiperidinderivate
MX2023004942A (es) Compuestos biciclicos y usos de los mismos para el tratamiento de enfermedades.
ATE549024T1 (de) Chinazolin-kaliumkanalhemmer
TW200504402A (en) Antimicrobial lenses, processes to prepare them and methods of their use
TW200700066A (en) Compounds for inhibiting ksp kinesin activity
ATE334681T1 (de) Verwendung von pteridinderivaten für die behandlung von erhöhtem hirndruck
NO20055563L (no) Midler for behandlingen av lavere abdominale lidelser
DK1438034T3 (da) Anvendelse af -phenyl-3-dimethylaminiopropanforbindelser til behandling af urininkontinens
HRP20051005A2 (en) Process for the preparation of nonpeptide substituted spirobenzoazepine derivatives
TW200621703A (en) Alkylidene-tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
PH12022551033A1 (en) Solid forms of an s1p-receptor modulator
ATE345135T1 (de) Tropan-derivate mit dopamin-wiederaufnahme-hemmer-wirkung für die behandlung von ischämischen erkrankungen
MX2024005884A (es) Usos de compuestos biciclicos para el tratamiento de enfermedades.
ATE392212T1 (de) Verwendung eines proteasom-inhibitors zur behandlung fibrotischer erkrankungen
DE502005005652D1 (de) Heterocyclyl-substituierte nonadepsipeptide

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1605947

Country of ref document: EP